DGX — Quest Diagnostics Incorporated

Is DGX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Quest Diagnostics Incorporated (DGX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $241.76. The rating moved from Neutral to Overbought on August 5, 2026.

See all overbought Healthcare stocks →

AI analysis

Quest Diagnostics benefits from stable, recurring testing demand and scale advantages across diagnostics services. Near-term catalysts include increased diagnostic procedure effectiveness and adoption of AI-enabled workflows that can lift oncology-related testing volumes. The company’s cash flow profile and national lab footprint support competitive positioning and operational flexibility. Key headwinds are reimbursement pressure from payers, competition from other lab providers and hospital systems, and regulatory/privacy risks impacting digital patient channels. Over the next month, modest upside is expected from steady order flow and sector tailwinds for diagnostic services, while medium-term upside depends on sustaining margin dynamics and capturing growth in specialized molecular and biologic-related testing.

Key factors

  • Stable, recurring revenue from routine and diagnostic testing with defensive demand characteristics
  • Positive readthrough from diagnostic and screening technology adoption (AI-enabled navigation, improved biopsy workflows) that can expand testing volumes in oncology pathways
  • Solid cash flow generation and historically conservative balance-sheet management supporting operational flexibility
  • Exposure to growing needs for specialized testing (molecular, infectious disease, and potential viral‑vector/biologics testing) as advanced therapies commercialize
  • Scale and national lab footprint provide competitive advantages for payer contracts and large-referral relationships
  • Relative resilience in a quiet macro window with sector rotation favoring defensive healthcare exposures

Risks

  • Reimbursement pressure and payer strategic rationalization that could compress margins or reduce test volumes
  • Intense competition from LabCorp, hospital systems building in‑house testing, and niche specialty labs
  • Regulatory, privacy, or FTC actions affecting digital-health partners or data‑driven patient acquisition models
  • Slower-than-expected adoption of new diagnostic pathways or failure of AI/robotic procedure adoption to translate into durable test-volume growth
  • Operational risks (capacity constraints, supply-chain or lab-disruption events) that can impact throughput and margins
  • Macroeconomic or elective-procedure slowdowns that reduce non-urgent testing demand

See today's live rating, score and targets

Members see the live hourly rating for DGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.